Herpes

Professor Kleymann is an internationally accredited expert in the field of herpes viruses. As laboratory director of Bayer pharmaceutical research, he discovered the innovative herpes helicase-primase inhibitors for the treatment of herpes simplex infections. The research results were published on the title page of one of the most reputable medical journals.

New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease
Nature Medicine 8, 392 – 398 (2002)
Kleymann et. al.

The company AiCuris is currently conducting clinical phase II studies with humans to test the drug BAY 57-1293 = AIC 316 for the treatment of herpes labialis & herpes genitalis. Dr. Kleymann is an excellent professor at the renowned University of Tübingen, Germany, where he teaches biochemistry students at the interfaculty institute for biochemistry, an institute of the medical and chemical pharmaceutical faculty.